Search Result

Results for "

primary tumor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Adenosine Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (2) Aryl Hydrocarbon Receptor (1) Bcr-Abl (1) Carbonic Anhydrase (1) Dopamine Receptor (1) Drug Derivative (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) FGFR (2) HIF/HIF Prolyl-Hydroxylase (1) JAK (1) MEK (1) MetAP (1) Notch (1) Orphan Receptor (1) PD-1/PD-L1 (1) Phosphatase (1) Photosensitizer (1) PI3K (1) PROTACs (2) Proteasome (1) Protein Arginine Deiminase (1) Radionuclide-Drug Conjugates (RDCs) (1) Raf (1) Reactive Oxygen Species (1) STAT (1) STING (1) Transmembrane Glycoprotein (1) YAP (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (5) Neurological Disease (2)

By Targets:

ADC Antibody (1)

Adenosine Receptor (1)

Aldehyde Dehydrogenase (ALDH) (1)

Apoptosis (2)

Aryl Hydrocarbon Receptor (1)

Bcr-Abl (1)

Carbonic Anhydrase (1)

Dopamine Receptor (1)

Drug Derivative (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (3)

FGFR (2)

HIF/HIF Prolyl-Hydroxylase (1)

JAK (1)

MEK (1)

MetAP (1)

Notch (1)

Orphan Receptor (1)

PD-1/PD-L1 (1)

Phosphatase (1)

Photosensitizer (1)

PI3K (1)

PROTACs (2)

Proteasome (1)

Protein Arginine Deiminase (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Raf (1)

Reactive Oxygen Species (1)

STAT (1)

STING (1)

Transmembrane Glycoprotein (1)

YAP (1)

By Research Areas:

Cancer (27)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (5)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153450

JBI-589	Protein Arginine Deiminase	Cancer
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .

HY-153863

MS934	PROTACs MEK Raf	Cancer
MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-107999

CADD522 4 Publications Verification	Reactive Oxygen Species	Cancer
CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC₅₀ of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer .

HY-A0037

Lasofoxifene 4 Publications Verification CP-336156	Estrogen Receptor/ERR	Inflammation/Immunology Cancer
Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .

HY-147250A

Lirafugratinib hydrochloride RLY-4008 hydrochloride	FGFR	Cancer
Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC₅₀ of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .

HY-126730

Rubratoxin A	Phosphatase	Cancer
Rubratoxin A is a natural mycotoxin and competitive inhibitor of protein phosphatase 2A (PP2A) with an IC₅₀ of 170 nM. Rubratoxin A causes suppression of tumor metastasis and reduction of primary tumor volume in mouse xenografts .

HY-16477A

Talaporfin ME2906 free acid; Mono-L-aspartyl chlorin e6 free acid; NPe6 free acid	Photosensitizer	Cancer
Talaporfin sodium, can be used in intraoperative photodynamic therapy (PDT) with a 664-nm semiconductor laser, was evaluated for efficacy and safety in treating primary malignant parenchymal brain tumors .

HY-103407

PD 168568	Dopamine Receptor	Neurological Disease Cancer
PD 168568 is a orally active and potent dopamine receptor D₄ (DRD₄) antagonist. PD 168568 contains an isoindolinone and is selective for the D₄ receptor versus D₂ and D₃, with K_i values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research .

HY-124875

Arylsulfonamide 64B HIF inhibitor 64B	HIF/HIF Prolyl-Hydroxylase	Neurological Disease
Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the hypoxia-induced factor (HIF)*. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary* tumor growth and metastasis of uveal melanoma mouse model .**

HY-147250

Lirafugratinib RLY-4008	FGFR	Cancer
Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC₅₀ of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .

HY-119618

R1498	Endogenous Metabolite	Cancer
R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .

HY-163545

Tc-Me2P	Drug Derivative	Cancer
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .

HY-A0038

Lasofoxifene tartrate 4 Publications Verification CP-336156 tartrate	Estrogen Receptor/ERR	Endocrinology Cancer
Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-P9983

Lintuzumab SGN-33; HuM-195	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .

HY-144670

ALDH3A1-IN-1	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC₅₀ of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with docetaxel .

HY-P991328

MAb604.107	Notch	Cancer
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .

HY-133016

M8891	MetAP	Cardiovascular Disease Cancer
M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC₅₀ of 54 nM and a K_i of 4.33 nM. M8891 does not inhibit MetAP-1 (IC₅₀>10 µM) . M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity .

HY-W338764

AHR agonist 3	Apoptosis Aryl Hydrocarbon Receptor	Cancer
AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research .

HY-P99229

Upifitamab 1 Publications Verification	ADC Antibody	Cancer
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .

HY-105017

Evodenoson ATL 313; DE 112	Adenosine Receptor	Infection Inflammation/Immunology
Evodenoson is a selective agonist of the A_2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .

HY-149913

NR2F1 agonist 1 1 Publications Verification	Orphan Receptor	Cancer
NR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model .

HY-110243

CAIX Inhibitor S4 1 Publications Verification	Carbonic Anhydrase	Cancer
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a K_i of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (K_i=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .

HY-155446

di-DTPA-LTL	Others	Inflammation/Immunology Cancer
di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with ¹¹¹In (indium) and ¹³¹I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled ¹¹¹In) into the patients .

HY-108417

Debio 0617B	STAT JAK Bcr-Abl	Cancer
Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34 ⁺ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors .

HY-146260

NVP-CLR457	PI3K	Cancer
NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity .

HY-164689

Cadmium pyrithione	Proteasome	Cancer
Cadmium pyrithione is a metal compound that inhibits protein deubiquitinase activity. Cadmium pyrithione treatment results in significant accumulation of ubiquitinated proteins in cancer cells and primary leukemia cells. Cadmium pyrithione strongly inhibits the activity of proteasome deubiquitinase (such as USP14 and UCHL5), but has a smaller inhibitory effect on 20S proteasome activity. The anticancer activity of Cadmium pyrithione is associated with the induction of apoptosis through caspase activation. Furthermore, Cadmium pyrithione inhibition inhibited proteasome function and suppressed tumor growth in animal xenograft models .

HY-149295

PROTAC ERα Degrader-4	PROTACs Estrogen Receptor/ERR Apoptosis	Cancer
PROTAC ERα Degrader-4 (Compound ZD12) is a highly potent and selectivePROTAC ERα degrader (K_i: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER ⁺ breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.

HY-162874

diABZI-V/C-DBCO	STING	Inflammation/Immunology Cancer
diABZI-V/C-DBCO (Compound 3) is a potent STING agonist. diABZI-V/C-DBCO can release diABZI-amine upon activation by cathepsin B to activate STING, leading to the production of interferons and other immune-stimulatory molecules, thereby enhancing the immune system's response to tumors. The EC₅₀ values for diABZI-V/C-DBCO and diABZI-amine in activating STING in THP1-Dual cells are 1.47 and 0.144 nM, respectively, and in primary mouse splenocytes, the EC₅₀ values are 7.7 and 0.17 μM, respectively. diABZI-V/C-DBCO can be used in cancer immunotherapy research .

Cat. No.	Product Name

HY-L188

Anti-Brain Cancer Compound Library	1,736 compounds
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 1,736 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

Anti-Brain Cancer Compound Library

1,736 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,736 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L0107V

Life Chemicals Natural Product-like Compound Library	13,236 compounds
Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. Nowadays, new drugs based on Natural products are successfully applied to treat tumors, viral and bacterial diseases, and nervous disorders. In response to the current drug discovery demand, we created this natural product-like compound library with 13,236 in-stock synthetic compounds similar to natural ones. The library was designed by 2D fingerprint similarity filtering, chemical descriptor-based and natural-likeness scoring selection. These compounds are useful tools for high throughput screening (HTS) and high content screening (HCS) programs.

Life Chemicals Natural Product-like Compound Library

13,236 compounds

Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. Nowadays, new drugs based on Natural products are successfully applied to treat tumors, viral and bacterial diseases, and nervous disorders. In response to the current drug discovery demand, we created this natural product-like compound library with 13,236 in-stock synthetic compounds similar to natural ones. The library was designed by 2D fingerprint similarity filtering, chemical descriptor-based and natural-likeness scoring selection. These compounds are useful tools for high throughput screening (HTS) and high content screening (HCS) programs.

Cat. No.	Product Name	Target	Research Area